

Cryptococcus Antigen Titer, Lateral Flow Assay, Pleural Fluid

### Overview

#### **Useful For**

Diagnosis of infection with Cryptococcus species

#### **Method Name**

Only orderable as a reflex. For more information see PLFA / *Cryptococcus* Antigen Screen, Lateral Flow Assay, Pleural Fluid.

Lateral Flow Assay (LFA)

#### NY State Available

Yes

# Specimen

### Specimen Type

Pleural Fluid

#### Specimen Required

Only orderable as a reflex. For more information see PLFA / *Cryptococcus* Antigen Screen, Lateral Flow Assay, Pleural Fluid.

# Container/Tube: Sterile vial Specimen Volume: 0.5 mL

#### Forms

If not ordering electronically, complete, print, and send <u>Infectious Disease Serology Test Request</u> (T916) with the specimen.

#### Specimen Minimum Volume

0.25 mL

#### **Reject Due To**

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

#### Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Pleural Fluid	Refrigerated (preferred)	21 days	



Cryptococcus Antigen Titer, Lateral Flow Assay, Pleural Fluid

Frozen	30 days	

### Clinical & Interpretive

#### **Clinical Information**

Cryptococcosis is an invasive fungal infection caused by *Cryptococcus neoformans* or *Cryptococcus gattii*. *C neoformans* has been isolated from several sites in nature, particularly weathered pigeon droppings. *C gattii* was previously associated with tropical and subtropical regions only; however, more recently this organism has also been found to be endemic in British Columbia, along the Pacific Northwest and in the Southeastern US.

Infection is usually acquired via the pulmonary route. Patients are often unaware of any exposure history. Approximately half of the patients with symptomatic disease have a predisposing immunosuppressive condition such as AIDS, steroid therapy, lymphoma, or sarcoidosis. Symptoms may include fever, headache, dizziness, ataxia, somnolence, and cough. While the majority of *C neoformans* infections occur in immunocompromised patient populations, *C gattii* has a higher predilection for infection of healthy individuals.

In addition to the lungs, cryptococcal infections frequently involve the central nervous system (CNS), particularly in patients infected with HIV. Mortality among patients with CNS cryptococcosis may approach 25% despite antibiotic therapy. Untreated CNS cryptococcosis is invariably fatal. Disseminated disease may affect any organ system and usually occurs in immunosuppressed individuals.

#### **Reference Values**

Only orderable as a reflex. For more information see PLFA / *Cryptococcus* Antigen Screen, Lateral Flow Assay, Pleural Fluid.

#### Interpretation

The presence of cryptococcal antigen in pleural fluid is indicative of infection with Cryptococcus species.

Monitoring cryptococcal antigen levels to determine response to therapy is discouraged, as antigen levels may persist despite adequate treatment and disease resolution.

A negative result indicates lack of infection; however rare cases of false-negative results have been reported. Fungal culture should always be ordered alongside antigen testing.

#### Cautions

A negative result does not preclude diagnosis of cryptococcal infection, particularly if the patient is at risk for cryptococcosis and shows symptoms consistent with this disease.

False-positive results may occur in patients with trichosporonosis or infection with Capnocytophaga species.

#### **Clinical Reference**

1. Binnicker MJ, Jespersen DJ, Bestrom JE, Rollins LO. Comparison of four assays for the detection of cryptococcal antigen. Clin Vaccine Immunol. 2012;19(12):1988-1990. doi:10.1128/CVI.00446-12

2. Howell SA, Hazen KC, Brandt ME. Candida, cryptococcus, and other yeast of medical importance. In: Manual of Clinical



Cryptococcus Antigen Titer, Lateral Flow Assay, Pleural Fluid

Microbiology. 11th ed. ASM Press; 2015:1984-2014

3. Chang CC, Harrison TS, Bicanic TA, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM. [published correction appears in Lancet Infect Dis. 2024;24(8):e485. doi:10.1016/S1473-3099(24)00426-2]. Lancet Infect Dis. 2024;24(8):e495-e512. doi:10.1016/S1473-3099(23)00731-4

4. Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: What do we know now. Fungal Genet Biol. 2015;78:49-54. doi:10.1016/j.fgb.2014.10.003

# Performance

### **Method Description**

The *Cryptococcus* antigen (CrAg) lateral flow assay is a sandwich immunochromatographic assay. Specimens and diluent are added to a test tube and the lateral flow device is added. The test uses specimen wicking to capture gold-conjugated anti-cryptococcal antigen monoclonal antibodies and gold-conjugated control antibodies deposited on the test membrane. If cryptococcal antigen is present in the specimen, it binds to the gold-conjugated, anti-cryptococcal antigen antibodies. This complex wicks up the membrane and interacts with the test line, which has immobilized anti-cryptococcal antigen monoclonal antibodies. The antigen-antibody complex forms a sandwich at the test line causing a visible line to form. A valid test shows a visible line at the control line. Positive test results create 2 lines (control and specimen), while negative results form only the control line.(Package insert: CrAg Lateral Flow Assay. IMMY; Rev 06/27/2019)

PDF Report

No

Day(s) Performed Monday through Sunday

Report Available 2 days

Specimen Retention Time

7 days

Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Superior Drive

# Fees & Codes

#### Fees

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.



Cryptococcus Antigen Titer, Lateral Flow Assay, Pleural Fluid

• Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

### **Test Classification**

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

#### **CPT Code Information**

87899

#### LOINC<sup>®</sup> Information

Test ID	Test Order Name	Order LOINC <sup>®</sup> Value
PLFAT	Cryptococcus Ag Titer, LFA, PF	11473-6

Result ID	Test Result Name	Result LOINC <sup>®</sup> Value
48431	Cryptococcus Ag Titer, LFA, PF	11473-6